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Abstract
Introduction: Infiltration of breast tumors by tumor-infiltrating lymphocytes (TIL) has been associated with
sensitivity to anthracycline-based chemotherapy. However, it is unclear whether this is true within the estrogen
receptor-alpha (ER)-negative subset of breast tumors that frequently manifest high TIL levels.
Methods: The association of TIL with short-term and long-term clinical response to anthracycline-based therapy
was assessed in two independent ER-negative breast cancer cohorts in which patients were categorized as TIL-high
or TIL-low. We defined an eight-gene lymphocyte mRNA expression signature (including CD19, CD3D, CD48, GZMB,
LCK, MS4A1, PRF1, and SELL) and used unsupervised hierarchical clustering to examine the association between TIL
and short-term response to neoadjuvant chemotherapy in a previously published cohort of ER-negative tumors (n
= 113). We also examined the association between TIL and long-term chemotherapeutic efficacy in a second
cohort of ER-negative tumors (n = 255) with longer than 6 years of median follow-up by using tissue microarrays
and immunohistochemistry (IHC) for detection of CD3, CD8, CD4, CD20, and TIA-1.
Results: In patients with ER-negative tumors treated with neoadjuvant anthracycline-based chemotherapy,
pathologic complete responses (pCRs) were achieved by 23 (74%) of 31 TIL-high patients and 25 (31%) of 80 TIL-
low patients (odds ratio (OR), 6.33; 95% confidence interval (CI), 2.49 to 16.08; P < 0.0001). Multivariate logistic
regression with standard clinicopathologic features demonstrated that only tumor size (P = 0.037) and TIL status (P
= 0.001) were independent predictors of anthracycline response. In the second cohort, adjuvant anthracycline-
based therapy was associated with increased disease-free survival (DFS) only in patients with high levels of
intraepithelial CD3
+ TIL (P = 0.0023). In contrast, outcomes after CMF treatment (cyclophosphamide, methotrexate,
and fluorouracil) showed no association with CD3 status. In both cohorts, cytotoxic T-cells were the primary TIL
subtype associated with anthracycline sensitivity. Finally, TIL significantly predicted anthracycline sensitivity for both
the Her2-positive and triple-negative tumor phenotypes.
Conclusions: ER-negative breast cancers with high levels of TIL have heightened sensitivity to anthracycline-based
chemotherapy, as assessed by the immediate response to neoadjuvant therapy and long-term outcome following
adjuvant therapy. Investigations of TIL-based predictive tests to identify patients likely to benefit from
anthracycline-based treatments are warranted.
Introduction
The use of adjuvant systemic therapy for breast cancer
has increased substantially in the last few decades, and
is now a mainstay modality in clinics worldwide.
Although adjuvant chemotherapy has significantly
improved patient management, a fundamental limitation
of this approach is that many patients fail to benefit
from therapy, and physicians are frequently unable to
predict the responses of individual patients to a given
regimen. As such, much effort has been directed in
recent years toward identifying clinical and biological
predictive features to better tailor therapy to the needs
of individual patients.
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ving anthracyclines such as doxorubicin or epirubicin)
has been used clinically for more than two decades and
has largely supplanted first-generation regimens such as
CMF [1]. Anthracyclines are thought to exert their
effects through a variety of mechanisms including inter-
calation of DNA, cross-linking of DNA to proteins, and
generation of free radicals [2]. Nevertheless, the precise
mechanisms by which anthracyclines exert their thera-
peutic effects in vivo remain unclear, nor has significant
progress been made in establishing predictive biomar-
kers to identify patients likely to derive benefit from
anthracycline-based therapy [2,3]. For example, aberra-
tions of HER2 and TOP2A initially showed promise as
anthracycline-response predictors, but have failed to
demonstrate consistent clinical utility [2].
Attention has focused recently on the prognostic and
predictive potential of antitumor immune responses,
detected indirectly via gene expression signatures derived
from tumor-infiltrating lymphocytes (TIL) or directly via
immunohistochemical TIL staining. In breast cancer, TIL
have been shown in several studies to correlate with favor-
able long-term prognosis, although primarily for hormone
receptor-negative, Her2-positive, or high grade/highly pro-
liferative lesions [4-10]. Denkert et al. [11] recently
reported that TIL were associated with a favorable
response to neoadjuvant anthracycline/taxane therapy in
two large breast cancer cohorts, providing compelling evi-
dence that TIL could potentially serve as predictive mar-
kers for anthracycline-based therapy. However, no such
studies have been conducted specifically with the ER-nega-
tive breast cancer subset. This is important for two rea-
sons: first, pathologic complete response to neoadjuvant
chemotherapy, defined as the complete absence of invasive
tumor cells in the breast and lymph nodes after treatment,
occurs almost exclusively in tumors negative for ER
[12-15]; second, ER-negative tumors typically feature
higher levels of TIL than do ER-positive tumors
[6,11,16-18]. Therefore, our objective in this study was to
determine whether TIL correlate with sensitivity to
anthracycline-based chemotherapy in ER-negative breast
cancer. To do so, we examined two independent cohorts
of ER-negative breast cancer cases. One cohort received
anthracycline-based therapy in the neoadjuvant setting,
permitting the assessment of short-term clinical responses
to therapy. The second cohort included patients with
long-term follow-up treated with anthracyclines in the
adjuvant setting, allowing us to examine overall and dis-
ease-free survival rates after systemic therapy.
Materials and methods
Neoadjuvant chemotherapy cohort
To assess the relationship between TIL and short-term
response to chemotherapy, we analyzed publically
available gene expression data [19] derived from pre-
treatment incisional or core tumor biopsies from a
cohort of patients with ER-negative invasive ductal
breast carcinomas. Note that the original publication
reporting analysis of gene signatures and treatment
response [19] has since been retracted because of con-
cerns regarding the statistical methods used to generate
predictive models (see Lancet Oncol 2011, Feb; 12:116
and Lancet Oncol 2010 Sep; 11:813-814). However, our
analysis is based on original data obtained from the
Gene Expression Omnibus website (http://www.ncbi.
nlm.nih.gov/geo; accession number GSE6861) and is
therefore not affected by this issue. Clinical characteris-
tics of the study cohort are summarized in Table 1. All
patients were enrolled in the EORTC 10994/BIG 00-01
clinical trial and received chemotherapy with either FEC
(fluorouracil, epirubicin, and cyclophosphamide for six
cycles) or TET (three cycles of docetaxel followed by
three cycles of docetaxel plus epirubicin) as primary
(neoadjuvant) therapy. The primary end point was
pathologic complete response (pCR) versus residual dis-
ease (RD).
Table 1 Characteristics of all assessed patients in the
EORTC and MBTB cohorts
EORTC (n = 113) MBTB (n = 255)
Case status Number % Number %
Age at diagnosis <50 years 56 50% 85 33%
≥50 years 57 50% 168 66%
Tumor size ≤2 cm 3 3% 51 20%
<2 cm to ≤5 68 60% 142 56%
>5 cm 42 37% 39 15%
Unknown 0 0 23 9%
Nodal status Negative 42 37% 88 35%
Positive 71 63% 142 56%
Unknown 0 0 25 10%
Grade 1-2 36 32% 120 47%
3 65 58% 119 47%
Unknown 12 11% 16 6%
ER
a Negative 113 100% 255 100%
Positive 0 0 0 0
PR
b Negative 110 97% 212 84%
Positive 3 3% 41 16%
Unknown 0 0 2 <1%
Her2
c Negative 83 73% 157 62%
Positive 30 27% 58 23%
Unknown 0 0 40 16%
Assessed cases were all invasive ductal carcinomas.
aER-negative status
defined as <10% of tumor cells stained positive for ER by IHC (EORTC) or <10
fmol/mg protein (ligand-binding assay; MBTB);
bPR-negative status defined as
<10% of tumor cells stained positive for PR by IHC (EORTC) or ≤15 fmol/mg
protein (ligand-binding assay; MBTB);
cHer2-positive status inferred based on
microarray data (EORTC) or determined by an IHC score of 3 (MBTB).
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To determine whether lymphocyte-associated gene
expression correlated with pCR rates, we analyzed
microarray data from the neoadjuvant (EORTC) cohort
and obtained an eight-gene TIL signature by using the
following steps. We first compiled a list of genes with
known biological functions that are expressed at high
levels by lymphocytes, based on information in the
BioGPS gene portal (http://biogps.gnf.org). Expression
data for these genes were compiled and z-normalized
(that is, number of standard deviations from the mean).
For genes with redundant probe sets, only those probes
with the highest interquartile range were selected. To
enrich for genes with expression patterns consistent
with a lymphocyte cell of origin, expression values of all
genes were Spearman correlated with those of CD247
(CD3-zeta chain) and MS4A1 (CD20), which were cho-
sen as specific and prototypical T- and B-lymphocyte
genes, respectively. Only genes that correlated to CD247
or MS4A1 with a Spearman R value of 0.7 or greater
were retained, resulting in a list of 33 genes. With this
gene set, cases were grouped by unsupervised hierarchi-
cal clustering using the centroid method and euclidean
distance as the similarity metric (performed with Cluster
3.0). Heat maps and cluster dendograms were produced
using Java TreeView.
We further refined the TIL signature by assessing dif-
ferential expression of each gene in pCR versus RD
cases and selecting genes with a Mann-Whitney t test P
value less than 0.05. The final eight-gene signature
included CD19, CD3D, CD48, GZMB, LCK, MS4A1,
PRF1,a n dSELL. Data corresponding to this signature
were used to cluster the EORTC cases, as described
above. Two cases that failed to cluster with any of the
primary centroids were considered outliers and dis-
carded from further analysis, leaving a final assessed
cohort size of 111 cases. Univariate associations of TIL
status and pathologic parameters with pCR rates were
calculated using two-sided Fisher’se x a c tt e s t si nP r i s m
5 . 0( G r a p h P a d ,L aJ o l l a ,C A ) .M u l t i v a r i a t el o g i s t i c
regression models for prediction of pCR were con-
structed in SPSS Statistics 14 (SPSS, Chicago, IL).
Adjuvant chemotherapy cohort
To assess the relationship between TIL and long-term
outcome after adjuvant chemotherapy, we analyzed TIL
in primary tumor biopsies or resections taken before
adjuvant therapy from a cohort of patients with ER-
negative invasive ductal breast carcinomas registered by
the Manitoba Breast Tumor Bank (MBTB). Cases were
accrued between the years 1988 and 2000 and had a
median follow-up time of 83 months. Clinical character-
istics of the study cohort are summarized in Table 1
and Additional file 1 (Supplementary Table S1). All
selected cases were determined to be ER-negative by a
single central provincial clinical laboratory and subse-
quently managed as ER-negative cases at a single pro-
vincial cancer center, where adjuvant systemic therapy
was administered to 61% of the cohort. Of these
patients, 58% were treated with CMF (cyclophospha-
mide, methotrexate, fluorouracil), and 37% were treated
with one of several anthracycline-based regimens (for
example, AC, CAF, CEF, where A is Adriamycin/doxor-
ubicin, and E is epirubicin). Disease-free survival (DFS)
was defined as the time from surgery to the first
instance of disease recurrence or disease-specific death,
and overall survival as the time to death from all causes.
The MBTB has approval from the Research Ethics
Board, Faculty of Medicine, University of Manitoba, to
collect, store, and distribute anonymous cases from its
archive under the Canadian Tri-Council Policy State-
ment waiver of consent. The current study was con-
ducted with approval from the University of British
Columbia/British Columbia Cancer Agency Research
Ethics Board.
Tissue microarray construction
An initial cohort of 255 ER-negative cases was selected
on the basis of (a) ER-negative status defined by ligand-
binding analysis of <10 fmol/mg protein; (b) invasive
ductal carcinoma components occupying more than
20% of the tumor section, and (c) no prior therapy. To
construct a tissue microarray (TMA), all cases were
rereviewed to confirm and select areas for coring of cor-
responding blocks. Duplicate tissue cores (0.6 mm dia-
meter) were taken from central cellular areas of each
tumor with a tissue arrayer instrument (Beecher Instru-
m e n t s ,S i l v e rS p r i n g ,M D ) .P r i o ru s ea n de x h a u s t i o no f
some tissue cores reduced the interpretable cohort size
to approximately 160, depending on the TIL marker
analyzed.
Immunohistochemistry and TMA scoring
Immunohistochemistry (IHC) was performed for CD3,
CD8, CD4, CD20, and TIA-1 on deparaffinized sections
from TMAs by using a Ventana Discovery XT autostai-
ner (Ventana, Tucson, AZ). Ventana’ss t a n d a r dC C 1
protocol was used for antigen retrieval. Primary antibo-
dies used are as follows (clone, supplier, animal source,
concentration): CD3 (RM-9107, Lab Vision, rabbit, 1/
150); CD8 (RM-9116, Lab Vision, rabbit, 1/100); CD4
(MS-1528, Lab Vision, mouse, 1/10); CD20 (polyclonal,
catalogue no. RB-9013, Lab Vision, rabbit, 1/250); TIA-1
(TIA-1, Abcam, mouse, 1/50). TMA sections were incu-
bated with primary antibodies for 60 minutes at room
temperature followed by the appropriate cross-adsorbed,
biotinylated secondary antibody (Jackson Immunore-
search, West Grove, PA) for 32 minutes. Antibodies
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were counterstained with hematoxylin (Ventana) and
coverslipped manually with Cytoseal-60 (Richard Allan,
Kalamazoo, MI).
IHC scoring was undertaken by using a microscope
eyepiece grid to standardize the assessed area. In brief,
duplicate cores of each immunostained tumor were
reviewed at low magnification, and the core exhibiting a
tumor/stroma ratio closest to 50:50 and the highest den-
sity of positive cells was selected. This core was then
assessed at higher magnification (×20 objective) with a
grid overlaid on the center of the core. Under a ×20
objective magnification, this grid defined an area of 0.56
mm
2. The number of positive intraepithelial lympho-
cytes was quantified within the area of the grid (intrae-
pithelial localization was defined as lymphocytes within
tumor cell nests or in direct contact with tumor cells,
consistent with the method used by Denkert et al. [11]).
To account for variation in epithelial-stromal propor-
tions between different samples, intraepithelial TIL
levels were calculated by dividing the number of
observed intraepithelial TIL by the fraction of grid area
occupied by epithelium.
Statistical analysis of IHC data
All analyses were performed using Prism 5.0. Unless
otherwise specified, median values for TIL markers were
used as predetermined cut-points to define high versus
low cases. Associations of TIL with pathologic features
were evaluated with Fisher’s exact test. Survival out-
comes were assessed via Kaplan-Meier methods and
compared using Log-rank tests. All statistical tests were
two-sided, with significance established at P values less
than 0.05.
Additional validation datasets
We assessed publically available gene-expression data
from ER-negative breast cancers within three additional
cohorts (accessible via the Gene Expression Omnibus
website), the characteristics of which are as follows:
GSE21974, a cohort of 32 breast cancer patients (14 ER-
negative) treated with neoadjuvant epirubicin, cyclopho-
sphamide, and docetaxel (not previously published);
GSE19615 [20], a cohort of 115 breast cancers, 36 of
which were ER-negative and treated with adjuvant
anthracycline-based therapy (primarily AC and AC plus
taxol); and GSE18864 [21], a cohort of 28 triple-negative
breast cancers (24 with complete data) treated with
neoadjuvant cisplatin. We tested the eight-gene TIL sig-
nature in these cohorts by extracting expression data for
the eight genes and processing it as described above. In
each cohort, patients were divided into two groups
based on clinical outcome. For GSE21974, this was
based on pathologic complete response or residual
disease; for GSE19615, patients were divided based on
the presence or absence of distant recurrence after 36
months of follow-up; and for GSE18864, patients were
divided into good and poor response groups based on
Miller-Payne scores of 3, 4, or 5 versus scores of 0, 1, or
2, respectively. For each response group, the average
expression level of each gene was calculated and plotted
as a box-and-whiskers plot; Mann-Whitney t tests were
used to assess differences in overall TIL-signature
expression.
Results
TIL-enriched tumors are highly sensitive to neoadjuvant
anthracycline-based therapy
Clustering analysis of the neoadjuvant (EORTC) cohort
using an initial set of 33 lymphocyte-associated genes
revealed that the combined pCR rate of the two patient
clusters with the highest levels of TIL-gene expression
was significantly higher than that of the remainder (P =
0.0028, Fisher’s exact test). This gene list was further
refined to derive an eight-gene TIL signature including
CD19, CD3D, CD48, GZMB, LCK, MS4A1, PRF1,a n d
SELL (see Methods), that was used in subsequent ana-
lyses. Unsupervised clustering of invasive ductal cases
yielded three primary centroids based on relative expres-
sion of the TIL signature, as follows: (a) highly enriched
for the eight TIL genes, (b) intermediate levels of
expression, and (c) low TIL levels (Figure 1a). Cases in
the TIL-high cluster generally had expression levels of
0.5 to 1 standard deviations greater than the mean for
each gene (Figure 1b). The respective pCR frequencies
of the three clusters were as follows: 23/31 (74.2%), 16/
54 (29.6%), and 9/26 (34.6%). Because the pCR rates of
the TIL-low and intermediate clusters were not signifi-
cantly different (P = 0.80), we treated them as a single
TIL-low cluster in subsequent analyses. TIL status
showed no significant association with clinical para-
meters including tumor size, tumor grade, nodal status,
patient age, Her2 and PR status, and treatment regimen.
The difference in pCR rates between TIL-high and TIL-
low patients was highly significant in univariate analysis
(P < 0.0001; OR, 6.325; 95% CI, 2.487 to 16.08; Table 2).
The positive and negative predictive values for TIL sta-
tus were 74.2% and 68.8%, respectively, with an overall
accuracy of 70.3%. TIL status was associated with treat-
ment response to a similar extent in patients treated
with FEC (P = 0.0035) and those treated with TET (P =
0.0059; Table 2). In multivariate logistic regression ana-
lysis, the only standard clinical parameter with indepen-
dent predictive significance was tumor size (Table 3; P
= 0.037). Notably, TIL status maintained strong signifi-
cance in this analysis (P = 0.001; OR, 6.42; 95% CI, 2.08
to 19.8), demonstrating independence from standard
pathologic parameters.
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because they are expressed primarily by T and B lym-
phocytes. As shown in Figure 1a, the genes clustered
into separate B-cell (CD19 and MS4A1) and T-cell
groups (CD3D, LCK, CD48, SELL, GZMB, PRF1). To
determine the relative importance of each gene in the
signature, we individually assessed their associations
with outcome by comparing pCR rates in cases with
expression levels in the upper quartile with those of
cases at or below this cut-point (Figure 1c). Intriguingly,
both B-cell genes failed to individually predict pCR (P >
0.1), whereas all T-cell genes reached statistical signifi-
cance. GZMB, a marker of cytotoxic T lymphocytes
(CTL), was the strongest single predictor of pCR (P =
0.0008), performing equivalently to the mean expression
level of all eight genes.
We further assessed the association of the eight-gene
TIL signature with response to anthracycline-based ther-
apy in two small independent cohorts of ER-negative
breast cancer with publically available gene-expression
and clinical outcomes data (see Methods for details and
Additional file 1: Supplementary Figure S1). One cohort
consisted of both pre-chemo biopsies and post-chemo
surgical specimens; in this group, the samples from
complete clinical responders (both before and after che-
motherapy) featured significantly higher levels of TIL-
signature expression than did those with residual disease
(P < 0.001). The second cohort consisted of patients
treated with anthracycline-based therapy in the adjuvant
setting. When patients were categorized based on the
presence or absence of distant metastasis after 36
months of follow-up, TIL-signature expression was sig-
nificantly elevated in disease-free cases (P < 0.001).
To determine the association of the eight-gene TIL
signature with outcome in a distinct treatment setting,
we performed the same analysis on a cohort of patients
treated with neoadjuvant cisplatin therapy (Figure S1).
In contrast with the anthracycline-based cohorts
described thus far, TIL-signature expression was not ele-
vated in patients with favorable responses to cisplatin
therapy, suggesting that the eight-gene signature may be
associated with clinical response in a regimen-specific
manner.
Tumor-infiltrating T-cells are associated with disease-free
survival in patients treated with adjuvant anthracycline-
based therapy
Having found an association of TIL with short-term
outcome (pCR assessed after six cycles of chemother-
apy) in a cohort of patients receiving neoadjuvant
anthracycline-based therapy, we further explored this
relationship in a cohort of patients with invasive ductal
carcinoma who had been postsurgically treated with
adjuvant chemotherapy and for whom long-term out-
come data were available (MBTB cohort). We used IHC
to detect and quantify TIL expressing CD3 (T-cells) and
categorized patients into CD3-high and -low groups by
using the population median (six) as a cut-point (Figure
Figure 1 An eight-gene tumor infiltrating lymphocyte (TIL)
signature is associated with pathologic complete response
(pCR) after neoadjuvant chemotherapy in the EORTC cohort. (a)
Heat map displaying gene (y-axis) and case clusters (x-axis). The TIL-
high and TIL-low groups with respective rates of pCR are indicated.
Colors correspond to z-normalized expression levels. (b) Average
expression levels ±SEM of each gene in the three primary centroids.
(c) Odds ratios (loge transformed, ±SEM) for probability of pCR
derived from Fisher’s exact tests for each gene in the TIL signature.
The TIL mean represents average expression levels across all eight
genes. High and low gene expression categories were assigned
using the upper quartile as the cut-point.
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patients, CD3-high status was significantly associated
with increased DFS (HR, 0.24; 95% CI, 0.08 to 0.77; P =
0.0160). High levels of CD3
+ TIL were not associated
with patient age, tumor size, or nodal status, but were
associated with Her2-negative (P = 0.0183) and PR-
negative (P = 0.0137) status, and strongly associated
with high tumor grade (P < 0.0001; Table 4). In agree-
ment with our findings from the EORTC cohort, anthra-
cycline-based therapy increased both DFS (HR, 0.28;
95% CI, 0.12 to 0.63; P = 0.0023) and overall survival
(HR, 0.28; 95% CI, 0.13 to 0.61; P = 0.0014) for CD3-
high patients, but did not significantly improve survival
for CD3-low patients (DFS HR, 0.66; 95% CI, 0.33 to
1.35; P = 0.2550; Figure 2c). The corresponding 5-year
DFS rates within the CD3-high group were 35.1% for
patients who did not receive systemic therapy and 86.7%
for anthracycline-treated patients (Fisher’s exact test: P
= 0.0016; OR, 12.00; 95% CI, 2.34 to 61.55). In contrast,
the DFS rates of CD3-low patients were not significantly
different between untreated and anthracycline-treated
groups (35.8% and 50.0%, respectively; Fisher’s exact
test, P = 0.3754; OR, 1.82; 95% CI, 0.56 to 5.93).
CMF chemotherapy was administered to approxi-
mately one third of the patients in this cohort. Unlike
anthracycline-based therapy, CMF effectively increased
Table 2 Two-sided Fisher’s exact tests for association of clinical variables and TIL-signature status with probability of
pathological complete response (pCR) in the EORTC cohort
Total (n = 111) FEC treated (n = 54) TET treated (n = 57)
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Size T3 vs T1/T2 0.39 (0.17-0.89) 0.0292 0.60 (0.19-1.87) 0.4103 0.25 (0.19-1.87) 0.0278
Grade 3 vs 1/2 2.80 (1.19-6.61) 0.0226 2.35 (0.73-7.56) 0.1684 2.00 (0.58-6.86) 0.3681
Node 1 vs 0
a 0.82 (0.38-1.78) 0.6927 1.05 (0.34-3.24) 1.0000 0.65 (0.22-1.92) 0.5823
Age ≥50 vs <50 0.89 (0.42-1.89) 0.8913 1.29 (0.43-3.82) 0.7827 0.62 (0.22-1.77) 0.4311
Her2 A vs N
b 1.21 (0.52-2.81) 0.6722 2.03 (0.53-7.72) 0.3243 0.81 (0.27-2.46) 0.7824
TET vs FEC 1.22 (0.57-2.59) 0.7022 NA NA NA NA
TIL high vs low 6.33 (2.49-16.08) <0.0001 6.48 (1.82-23.10) 0.0035 6.84 (1.65-28.39) 0.0059
a1, lymph node positive; 0, lymph node negative.
bA, amplified; N, not amplified.
Table 3 Logistic regression model for prediction of
pathologic complete response (pCR) in the EORTC cohort
(n = 99)
OR (95% CI) P value
Size T3 vs T1/T2 0.38 (0.15-0.95) 0.037
Grade 3 vs 1/2 1.77 (0.76-4.11) 0.186
Node 1 vs 0
a 0.62 (0.25-1.51) 0.620
Age ≥50 vs <50 0.69 (0.27-1.75) 0.433
Her2 A vs N
b 1.97 (0.66-5.92) 0.227
FEC vs TET 0.64 (0.26-1.59) 0.337
TIL high vs low 6.42 (2.08-19.83) 0.001
a1, lymph node positive; 0, lymph node negative;
bA, amplified; N, not
amplified.
Figure 2 Long term outcome of patients according to adjuvant
chemotherapy and CD3 status. Representative
immunohistochemistry (IHC) staining of CD3 (×40 objective)
demonstrating (a) low and (b) dense intraepithelial infiltration of
CD3
+ TIL. (c) Disease-free survival (DFS) of patients treated with
anthracycline-based regimens or CMF (cyclophosphamide,
methotrexate, fluorouracil) relative to systemically untreated patients
in CD3-high (n = 77) and -low (n = 79) subgroups. Ptrend, log-rank
test for trend.
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to 0.76; P = 0.0064) and CD3-low patients (HR, 0.34;
95% CI, 0.17 to 0.67; P = 0.0017; Figure 2c). Because no
significant clinical differences were found between
anthracycline- and CMF-treated patients in this cohort,
this implies that CD3 status is predictive of treatment
response specifically for anthracycline-based regimens.
Although CD3-high, anthracycline-treated patients had a
higher 5-year DFS rate than did the CMF-treated
patients (86.7% and 70.8%, respectively), this did not
reach statistical significance.
Cytotoxic T-cells are the primary TIL subtype associated
with anthracycline sensitivity
In addition to CD3
+ T-cells, we also assessed CD20
+
TIL (B-cells) in the adjuvant cohort. Consistent with our
results from the neoadjuvant cohort, anthracycline ther-
apy was somewhat more effective for CD20-high than
for CD20-low patients, but this did not reach statistical
significance (data not shown), indicating that T-cells are
the more relevant TIL subset. CD3 staining detects both
CD8
+ (cytotoxic) and CD4
+ (helper) T-cell populations;
as such, we further assessed these subpopulations to
determine their relative contributions to the correlation
of CD3 with treatment response. As expected, CD3
levels were strongly correlated with CD4
+ and CD8
+
TIL (Figure 3a). However, in terms of absolute cell
numbers, CD3-high status was most closely associated
with large numbers of CD8
+ cells (7.8-fold higher in
CD3 high versus low). When patients were categorized
according to high/low levels of CD8
+ and CD4
+ TIL,
anthracycline-based therapy was beneficial for CD8-high
(HR, 0.36; 95% CI, 0.15 to 0.84; P = 0.0177), but not for
CD8-low patients (HR, 0.74; 95% CI, 0.35 to 1.59; P =
0.4408; Figure 3b). In contrast, treatment efficacy
showed no association with CD4 status (Figure 3c),
suggesting that CD8
+ TIL are the dominant TIL pheno-
type in determining benefit from anthracycline-based
therapy. This is consistent with our observation that the
CTL effector gene GZMB was a strong predictor of
therapeutic response in the neoadjuvant cohort. To con-
firm this, we scored the adjuvant cohort for cells expres-
sing TIA-1, a component of cytolytic granules
characteristic of differentiated CTL and natural killer
cells [5,22-28]. TIA-1 was present at detectable levels in
58 of 137 assessable cases and correlated strongly with
CD8 (Spearman R =0 . 6 4 ;P < 0.0001). Among patients
treated with anthracycline-based therapy, no recurrences
occurred for those with high levels of TIA-1
+ TIL
(upper quartile or higher), whereas those with low levels
of TIA-1 had a DFS rate of only 29.6% (log-rank HR,
0.16; 95% CI, 0.05 to 0.52; P = 0.0027; data not shown).
Like CD3, TIA-1 had no significant prognostic relevance
for CMF-treated patients (log-rank HR = 0.60; 95% CI,
0.21 to 1.71; P = 0.3397). These data collectively suggest
that cytotoxic T-cells are a key component of the asso-
ciation between TIL and responsiveness to anthracy-
cline-based therapy in ER-negative breast cancer.
TIL predict anthracycline sensitivity in distinct molecular
subtypes of ER-negative breast cancer
Her2 overexpression is frequently observed in ER-nega-
tive breast cancer and is a well-known marker of poor
prognosis. While trastuzumab use has markedly
improved management of Her2-positive breast tumors,
standard chemotherapeutic approaches continue to play
a role in the treatment of these cancers. Although our
second cohort did not contain enough Her2-positive
cases treated with anthracyclines to permit rigorous sur-
vival analysis, we assessed clinical responses in the
Her2-positive subset of the neoadjuvant (EORTC)
cohort. Of seven cases classified as TIL-high, six
achieved a pCR (85.7%), compared with only eight of 23
TIL-low cases (34.8%; Fisher’s exact test: P = 0.0309;
OR, 11.25; 95% CI, 1.145 to 110.5).
Unlike ER-positive and Her2-positive breast tumors,
which are candidates for endocrine and trastuzumab
therapy, respectively, no targeted therapies for triple-
negative breast tumors (TN; those lacking ER, PR, and
Her2 overexpression) currently exist, making these a
priority of translational research efforts. We therefore
investigated whether our findings also applied to TN
tumors. Among cases with documented Her2, ER, and
PR status, TN tumors constituted 71% of the neoadju-
vant (EORTC) cohort and 61% of the adjuvant (MBTB)
cohort. In the neoadjuvant cohort, the predictive capa-
city of TIL status for anthracycline responsiveness in the
TN subset was comparable to that of the entire dataset;
the pCR rates of the TIL-high and -low groups were
73.9% and 30.9%, respectively (Fisher’se x a c tt e s t :P =
Table 4 Two-sided Fisher’s exact tests for association of
CD3 status
a and clinical parameters in the MBTB cohort
CD3 low CD3 high P value
Age at diagnosis <50 30 28 0.7442
≥50 50 53
Tumor size T1-T2 60 61 1.0000
T3 15 15
Nodal status Negative 28 48 0.6128
Positive 48 41
Grade 1-2 43 19 <0.0001
33 1 5 8
Her2 IHC 0-2 46 63 0.0183
32 7 1 5
PR
b Negative 63 75 0.0137
Positive 17 6
aCD3 high, >median level of CD3
+ cells per sample;
bligand-binding assay;
negative, ≤15 fmol/mg protein
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CD19 nor MS4A1 alone correlated with pCR, whereas
GZMB did so significantly (P = 0.0042). Similarly, in TN
tumors of the MBTB adjuvant cohort, anthracycline-
based therapy was associated with improved survival in
the CD3-high group (log-rank HR, 0.25; 95% CI, 0.09 to
0.66; P = 0.0056), but not the CD3-low group (log-rank
HR, 0.65; 95% CI, 0.24 to 1.79; P = 0.4054; data not
shown). Consistent with the neoadjuvant cohort, CD8
+
(P = 0.0390) and TIA-1
+ (P = 0.0040) TIL were asso-
ciated with improved outcomes after anthracycline-
based therapy, but not CD4
+ or CD20
+ TIL. Therefore,
TIL (particularly CTL) are associated with sensitivity to
anthracycline-based therapy in the clinically challenging
triple-negative subset of breast cancer.
Discussion
We have demonstrated that a subgroup of ER-negative
breast cancer defined by high lymphocyte gene expres-
sion has a remarkably high rate (74%) of pathologic
complete response to neoadjuvant anthracycline-based
therapy. We have further shown that the clinical benefit
Figure 3 Additional TIL subsets and their relationship with CD3 status and anthracycline sensitivity. (a) TIL levels in CD3-high and -low
cases. Data represent average numbers of TIL expressing CD8, CD4, or CD20 ±SEM. ***P < 0.0001, Mann-Whitney t test. (b) Association of CD8
+
and (c) CD4
+ TIL with response to anthracycline therapy. Patients were categorized according to levels of CD8
+ and CD4
+ TIL and assessed for
disease-free survival (DFS) with respect to anthracycline-based therapy.
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restricted to patients with high numbers of tumor-infil-
trating T-cells, especially those of the CD8
+ and TIA-1
+
subsets. In contrast, TIL show no association with out-
come after classic CMF therapy.
Our findings are consistent with several prior reports.
In 2008, Hornychová et al. [29] observed high levels of
intraepithelial CD3
+ TIL in pretreatment biopsies of
patients who achieved pCR after neoadjuvant therapy
with doxorubicin and paclitaxel. Ladoire et al. [30] ana-
lyzed pre- and post-treatment samples from 56 patients
treated with neoadjuvant anthracycline-based therapy
and found that high ratios of CD8
+ to Foxp3
+ TIL
(putative regulatory T-cells (Tregs)) in surgical speci-
mens were correlated with a high rate of pCR. Consis-
tent with our own findings, they also reported that,
relative to pretreatment levels, TIA-1
+ and GzmB
+ TIL
(CTL) were significantly increased in the posttreatment
samples of patients who achieved pCR, but not in those
who had residual disease. Finally, Denkert et al. [11]
reported a significant relationship between TIL (identi-
fied by a combination of H&E assessment, IHC for CD3
and CD20, and expression analysis of several TIL genes
by PCR) and pathologic response to neoadjuvant anthra-
cycline/taxane therapy in a large group of 1,058 patients,
approximately one fourth of whom were ER-negative. As
such, based on our data and prior reports, TIL are con-
sistently associated with improved outcomes after
anthracycline-based therapy. Intriguingly, in 2001,
Demaria et al. [31] observed in a small group of breast
cancer patients (n = 25) treated with neoadjuvant pacli-
taxel therapy that levels of CD3
+ TIL increased in the
tumor bed after treatment, and that this correlated with
therapeutic response. Although our data imply that TIL
are not related to therapeutic responses in patients trea-
ted with cisplatin or CMF, the Demaria study neverthe-
less suggests that the correlation of TIL with treatment
response may not be restricted entirely to anthracycline-
based therapy.
It is important to note that TIL have been correlated
with improved survival in several breast cancer studies
to date, the association being observed primarily in
high-grade, ER-negative, or Her2-positive lesions [4-10].
Given that many of the patients evaluated in these stu-
dies were not systemically treated, TIL may also be a
feature of breast cancers with a naturally favorable clini-
cal outcome, which could have implications for the
interpretation of the results in our study. This may also
be the case for a variety of other cancer types, including
malignancies of the colon [32], ovary [33], lung [34],
and bladder [35]. In the systemically untreated patients
of our long-term follow-up cohort, however, those with
high levels of CD3
+ or CD8
+ TIL had only a modest,
nonsignificant survival advantage over those with low
TIL levels. It is therefore unlikely that the inherent asso-
ciation between TIL and improved prognosis was a sig-
nificant underlying feature of our observations with
regard to chemotherapy response.
The mechanism underlying the relationship between
TIL and anthracycline sensitivity in humans is not cur-
rently understood. It is possible that TIL may not be
causally related to therapeutic outcomes, and are instead
biomarkers of an unknown feature that burdens tumors
with anthracycline sensitivity. However, it is equally
plausible that TIL directly mediate treatment responses.
Indeed, this is supported in preclinical models, discussed
here at length.
Four primary explanations for the relationship
between anthracyclines and immunity have arisen based
on observations in both the laboratory and the clinic
[36,37]. One possible scenario is that anthracyclines kill
or suppress Tregs in the tumor microenvironment, thus
relieving inhibition of the anti-tumor immune response.
For example, in the aforementioned study by Ladoire et
al. [30], Foxp3
+ TIL were significantly reduced in the
tumor bed after successful neoadjuvant anthracycline-
based therapy, whereas their levels were unchanged in
patients with residual disease. However, interpretation
of this result is difficult because patients in the Ladoire
study received a regimen (FEC) containing cyclopho-
sphamide, a drug known to deplete Tregs selectively at
low doses (as well as conventional T-cells at high doses)
[38-41]. Similarly, many of the drug combinations used
to treat patients in our study also included cyclopho-
sphamide. Further studies designed to elucidate the spe-
cific effects of anthracyclines on intratumoral Treg
populations will be required to determine the validity of
this concept.
A second possible mechanism is derived from obser-
vations that transient lymphopenia (induced therapeuti-
cally via low-dose total-body irradiation or by
myelosuppressive drugs such as cyclophosphamide) can
enhance immunotherapy in the context of adoptive
transfer or vaccination. Through a variety of mechan-
isms, therapeutic lymphopenia appears to trigger
homeostatic processes that favor the proliferation and
functionality of anti-tumor effector T-cells, while also
ameliorating tumor-induced immunosuppression [42].
However, considering the myelosuppressive properties
of cyclophosphamide, this idea does not account for our
observation that TIL are associated with outcome after
anthracycline-based but not CMF chemotherapy.
A third hypothesis is that chemotherapy can sensitize
tumor cells to T-cell-mediated cytotoxicity. For example,
Yang and Haluska [43] found that treatment of human
melanoma cell lines with either 5-fluorouracil or dacar-
bazine improved the efficacy of perforin/granzyme-
mediated killing by antigen-specific CTL. Similar results
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and doxorubicin [44]. Cyclophosphamide has also been
shown to sensitize mesothelioma cells to CTL killing,
although through a TRAIL (TNF-related apoptosis-indu-
cing ligand)-mediated effect [45]. Finally, doxorubicin
has been shown to induce Fas expression in breast can-
cer cell lines, leading to increased susceptibility to Fas
ligand-mediated apoptosis [46]. These studies collec-
tively suggest an attractive model involving cytotoxic
synergy between chemotherapy and the immune system.
Nevertheless, as with the myelosuppression model dis-
cussed above, this mechanism would support a relation-
ship between TIL and CMF therapy, which is not
observed in our study.
The fourth hypothesis is that anthracyclines, unlike
most chemotherapeutic drugs, induce immunogenic
tumor cell death and thereby function indirectly as
immunostimulatory agents [42]. Casares et al. [47] trea-
ted murine CT26 colon carcinoma cells with doxorubicin
and inoculated the dying cells into syngeneic hosts,
which resulted in protection from concurrent or subse-
quent challenge with live CT26 cells. Notably, this effect
was dependent on dendritic cells and CD8
+ T-cells and
was specific for the CT26 tumor line, indicating an
immunologic mechanism. In contrast, cells stimulated to
undergo apoptosis by using mitomycin-C, a non-anthra-
cycline DNA cross-linking agent, did not elicit protective
immunity. Obeid et al. [48] expanded on this work by
demonstrating that anthracyclines trigger preapoptotic
shuttling of calreticulin to the dying cell surface, where it
acts as an opsonin to stimulate phagocytosis and proces-
sing by dendritic cells. Compared with a variety of apop-
tosis-inducing drugs with various mechanisms of action
(including staurosporine, tunicamycin, mitomycin-C, and
etoposide), anthracyclines induced greater calreticulin
surface presentation on target cells, which correlated
with the ability to elicit protective immunity. Indeed,
blockade or knockdown of calreticulin in anthracycline-
treated cells abolished their immunogenicity in mice [48].
Finally, Apetoh et al. [49] demonstrated that doxorubicin
additionally causes the extracellular release of HMGB1
(high-mobility-group box 1), an endogenous ligand of
Toll-like receptor 4 (TLR4). HMGB1 stimulation of den-
dritic cells was necessary for processing and cross-pre-
sentation of antigens from dying tumor cells. The
authors further showed that breast cancer patients bear-
ing loss-of-function TLR4 alleles had significantly worse
prognosis when treated with anthracycline-based che-
motherapy [49]. Taken together, mounting evidence indi-
cates that anthracyclines have the rare ability to elicit
specific immunity against target cells via stimulation of
dendritic cells in a calreticulin and HMGB1/TLR-4-
dependent fashion. This may explain the observation that
anthracycline-based therapy appears most effective in
breast cancer patients with high levels of endogenous
tumor immunity, as well as the finding of Ladoire et al.
[30] that CTL accumulate in the tumor beds of patients
treated successfully with neoadjuvant anthracycline-
based therapy. One unanswered question is whether
anthracycline-based treatments can induce new tumor
antigen-specific T-cells (de novo immunity) or, alterna-
tively, augment the expansion or functional activity of
preexisting tumor-reactive T-cells.
An important confounding feature of our study is the
heterogeneous and multivalent chemotherapy used in
the assessed cohorts. Although we have emphasized
anthracyclines as the unifying components of the treat-
ments we assessed, it is difficult to determine the extent
to which anthracyclines are specifically responsible for
our observations. For example, many of the patients in
this study were treated with regimens involving taxanes,
which may also have clinically relevant effects on host
immunity [31]. Furthermore, the potentially competing
or cooperative effects on tumor immunity that agents
such as anthracyclines, cyclophosphamide, and taxanes
may possess when administered sequentially or simulta-
neously are not currently understood. A second caveat
worthy of note pertains to the use of gene-expression
arrays to infer the presence of TIL. The use of IHC to
detect TIL is advantageous for several reasons, including
the ability to directly quantify cells that express a given
marker, as well as to accurately determine their specific
localization within a tissue. This information cannot be
acquired by using conventional methods of gene-expres-
sion analysis. Thus, although the data presented for the
eight-gene TIL signature reflect a relative abundance of
TIL, they lack the desirable single-cell resolution that is
achievable through IHC.
A further limitation of this study is that the adjuvant
cohort did not contain enough anthracycline-treated
cases to permit rigorous multivariate analysis (although
this was performed in the neoadjuvant cohort). This was
largely because ER-negative tumors constitute only
~30% of breast cancer cases, and CMF was the domi-
nant systemic regimen for breast cancer in Canada at
the time that this cohort was treated. Our additional
validation cohorts are also small for two primary rea-
sons: first, because many publically available datasets are
derived from fine-needle aspirates (as opposed to core
or open-biopsy specimens), and so may not accurately
reflect overall lymphocyte infiltration; and second,
because most cohorts contain both ER-positive and ER-
negative tumors, with relatively few cases of the latter.
Our observations thus warrant validation in large, inde-
pendent cohorts with long-term follow-up. Ultimately,
prospective trials of therapeutic outcome prediction will
be required to fully assess the clinical utility of the con-
cepts presented herein.
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detectable with standard IHC, may prove useful for
identifying patients who are likely to benefit from
anthracycline-based therapy. Moreover, our findings
suggest that patients with low TIL levels may benefit
most from alternative regimens such as CMF. In addi-
tion, our study provides support for the idea of combin-
ing anthracycline-based chemotherapy with
immunotherapeutic strategies such as cancer vaccines or
adoptive T-cell therapy to fully engage the host immune
response against breast cancer.
Conclusions
TIL that express cytotoxic markers are strongly asso-
ciated with favorable outcome after anthracycline-based
treatment of ER-negative breast cancer, including the
clinically challenging triple-negative subset. Further stu-
dies to develop TIL-based predictive and therapeutic
strategies for breast cancer are warranted.
Additional material
Additional file 1: Supplementary Figure S1 and Supplementary
Table S1. Figure S1 displays the associations of the genes from the
eight-gene TIL signature with clinical outcome in the four publically
available datasets assessed in this study (GEO accession number
GSE6861, the primary cohort treated with anthracycline-based therapy;
GSE21974 and GSE19615, two additional cohorts of anthracycline-treated
breast cancer patients; and GSE18864, a cohort treated with cisplatin).
Table S1 displays the clinical characteristics of the MBTB cohort,
organized by treatment category.
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